Cerebral pressure autoregulation in traumatic brain injury

Leonardo Rangel-Castilla, M.D., Jaime Gasco, M.D., Hariing J. W. Nauta, M.D., Ph.D., David O. Okonkwo, M.D., Ph.D., and Claudia S. Robertson, M.D.

1Division of Neurosurgery, University of Texas Medical Branch, Galveston; 2Department of Neurosurgery, Baylor College of Medicine, Houston, Texas; and 3Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

An understanding of normal cerebral autoregulation and its response to pathological derangements is helpful in the diagnosis, monitoring, management, and prognosis of severe traumatic brain injury (TBI). Pressure autoregulation is the most common approach in testing the effects of mean arterial blood pressure on cerebral blood flow. A gold standard for measuring cerebral pressure autoregulation is not available, and the literature shows considerable disparity in methods. This fact is not surprising given that cerebral autoregulation is more a concept than a physically measurable entity. Alterations in cerebral autoregulation can vary from patient to patient and over time and are critical during the first 4–5 days after injury. An assessment of cerebral autoregulation as part of bedside neuromonitoring in the neurointensive care unit can allow the individualized treatment of secondary injury in a patient with severe TBI. The assessment of cerebral autoregulation is best achieved with dynamic autoregulation methods. Hyperventilation, hyperoxia, nitric oxide and its derivates, and erythropoietin are some of the therapies that can be helpful in managing cerebral autoregulation. In this review the authors summarize the most important points related to cerebral pressure autoregulation in TBI as applied in clinical practice, based on the literature as well as their own experience.

(DOI: 10.3171/FOC.2008.25.10.E7)

Key Words • cerebral autoregulation • cerebral vasculature • intracranial hypertension • pressure autoregulation • traumatic brain injury

The outcome of severe TBI has improved with advances in intensive care monitoring and treatment, most notably in Lund, Sweden, and Richmond, Virginia, in the second half of the 20th century. An understanding of the physiology, pathophysiology, monitoring, and treatment of cerebral autoregulation is key in the evolution of the critical care management of severe TBI.

Cerebral pressure autoregulation is the specific intrinsic ability to maintain constant CBF over a range of blood pressures. Metabolic cerebral autoregulation is the ability of the brain to locally adjust CBF to meet cerebral metabolic requirements.27 Metabolic cerebral autoregulation is a distinct entity, and for the purpose of this review we focus on pressure autoregulation.

Cerebral pressure autoregulation is generally observed between a MABP of ~ 50 and 150 mm Hg (Fig. 1).27 Normal CBF in humans varies widely depending on tissue demands but averages around 50 ml/100 g brain tissue/min and is characteristically higher in children and adolescents and lower with advancing age.28 Irreversible neuron damage occurs in a time-dependent manner when CBF is below 10–15 ml/100 g/min, whereas reversible neuronal dysfunction has been noted at a CBF between 15 and 20 ml/100 g/min (Fig. 2).2 Pressure autoregulation mechanisms protect against cerebral ischemia due to hypotension and against excessive flow (malignant hyperemia) during hypertension, when capillary damage, edema, diffuse hemorrhage, and intracranial hypertension might otherwise result. The loss of or an impairment in cerebral pressure autoregulation carries important ramifications for patients with TBI.

Normal Physiology

Under normal physiological conditions, cerebral autoregulation is a complex process that involves myogenic, neurogenic, and metabolic mechanisms, possibly acting in combination. The myogenic component is the intrinsic ability of the vascular smooth muscle to con-
strict or dilate in response to changes in transmural pressure. This mechanism can be demonstrated in isolated vessel preparations in which alterations in the intravascular pressures trigger immediate changes in vessel diameter. The neurogenic mechanism occurs through an extensive nerve supply to midsized vessels. The activation of α-adrenergic sympathetic nerves shifts the limits of autoregulation toward higher pressures, and acute denervation (for example, neurogenic shock) shifts the limits of autoregulation toward lower pressures. During acute hypertensive episodes, the cerebral vasculature responds with vasoconstriction. The metabolic mechanism probably occurs in smaller vessels that are subject to changes in the local microenvironment that alter vasomotor response. For example, an uncompensated drop in blood pressure results in a decrease in CBF, which in turn leads to an accumulation of CO₂ and a depletion of O₂. These changes in the microenvironment cause vasodilation to return CBF back to a normal level. Variations in the PaCO₂ exert a profound influence on CBF, with an ~ 4% increase in CBF for every 1-mm Hg decrease in PaCO₂ and a 4% decrease in CBF for every 1-mm Hg increase in PaCO₂. This arteriolar response has been shown to be mediated by a local effect of H⁺ or in pH variations in the extracellular fluid surrounding vessels in the brain. The PaO₂ in the normal physiological range does not affect CBF, but when PaO₂ falls below 50 mm Hg, CBF increases dramatically.

Autoregulatory vasoconstriction is much smaller (maximum ~ 8–10% of baseline diameter) than autoregulatory vasodilation (up to 65% of baseline diameter). Consequently, much greater changes in CBV occur with hypotension than with hypertension. Autoregulatory vasoconstriction predominantly takes place in the largest arterioles (> 200 μm in diameter), although the bulk of the CBV is probably contained in smaller vessels, because they are so much more numerous, and in the venous system. Additionally, endothelium-related factors have been suggested to contribute to autoregulatory responses, and some studies have indicated a possible role for NO as a vasodilator during reduced CPP.

Pathophysiology of Cerebral Autoregulation in TBI

Across multiple studies, 49–87% of patients with severe TBI have demonstrated an absence of or impairment in autoregulation. Disturbed cerebral autoregulation has been shown to occur in patients after head injury, and in experimental models it has been observed even when...
Cerebral autoregulation in traumatic brain injury

Fig. 3. Graph revealing cerebral hemodynamics (flow velocity and MABP) and metabolism (jugular venous oxygen saturation and ETCO2) and their relationship to sROR test. $S_j O_2$ = jugular venous oxygen saturation.

the values of CPP and CBF are normal. Cerebral autoregulation can be impaired in any degree of TBI, even mild, and with normal ICP and MABP values. Patients in whom cerebral autoregulation is impaired or absent have a greater risk of cerebral ischemia if hypotension occurs. When cerebral autoregulation is impaired, sudden increases in MABP can be more easily transmitted into the microcirculation and can contribute to either areas of infarction or secondary hemorrhages and edema. Moreover, cerebral autoregulation determines the response to a number of drug treatments administered to a patient with severe TBI, including mannitol and pressors.

Impaired cerebral autoregulation may be a significant risk factor for secondary injury in the first few hours after severe TBI, when CBF is reduced in up to 60% of patients and when patients are most likely to be hemodynamically unstable. A reduction in CBF after severe TBI is due to the reduced metabolic demands of coma or may represent hypoperfusion or ischemia. Arteriovenous $O_2$ difference measurements demonstrate that even when CBF is reduced, it often exceeds metabolic requirements. However, in 27% of patients with severe TBI and CBF as low as 18 ml/100 g/min, AVDO$$_2$$ measurements have indicated that CBF does not meet the metabolic demands of the injured brain.

In the injured brain, cerebral autoregulation predicts CBV, and hence changes in ICP, with changing hemodynamic conditions. When autoregulation is intact, a decrease in CPP results in vasodilation (and increased CBV), leading to increased ICP due to impaired brain compliance. With defective cerebral autoregulation, any decrease in CPP, regardless of its baseline value, will produce a decrease in CBF. Cerebral blood flow will decrease linearly with CPP and thus may reach ischemic levels, worsening secondary injury.

Cerebral autoregulation is not an all-or-nothing phenomenon but more typically exists with various degrees of impairment and an irregular distribution throughout the injured brain. It has been shown that autoregulation impairment is worse on the side of the brain in which mass lesions are present. It is well known that CBF and cerebral autoregulation are heterogeneous after TBI and tend to be reduced in the immediate vicinity of a contusion. This finding can be explained by interhemispheric ICP gradients, local tissue pressure gradients leading to mass shift, and asymmetry of CVR due to a heterogeneous pattern of endothelial dysfunction. There is a surprising but established correlation between the asymmetry of autoregulation and a poor outcome. Although incompletely understood, a poor outcome is more strongly correlated with asymmetric autoregulation than with globally altered autoregulation. Patients who died after TBI had a worse and mainly asymmetrical autoregulation.

An understanding of the state of cerebral autoregulation permits more individualized critical care of a patient with TBI, as reflected in the most recent guidelines on the management of severe TBI. In patients with impaired autoregulation, attempts to improve CPP values by using vasoressors can precipitate a dangerous CBF (malignant hyperemia). Thus, in the new guidelines, it has been pointed out that patients with intact autoregulation tolerate higher CPP values (70 mm Hg) than patients with impaired autoregulation, whose target CPP should not be above 60 mm Hg.

Methods to Assess Cerebral Pressure Autoregulation

Measuring cerebral pressure autoregulation may provide clinically useful information in treating patients with TBI. Cerebral autoregulation is probably best understood not as a single physical quantity with a simple metric, but rather as a distributed phenomenon, perhaps reflecting large vascular beds. The challenge in establishing appropriate measurement modalities for cerebral autoregulation is made more difficult by other variables that can influence CBF (PaCO$$_2$$, brain activation, O$_2$ content, hematocrit, and temperature). At present, no single method can be regarded as a gold-standard measure of cerebral autoregulation. So far, there are 2 methods for assessing the status of cerebral autoregulation: static and dynamic. Of the 2, the dynamic measure has greater clinical relevance.

Static Autoregulation

Most investigators of cerebral autoregulation have looked at the steady-state relationship between CBF and CPP or MABP without considering the time course of changes in flow following changes in pressure (Fig. 3). This approach is the static type used to derive the classic autoregulation curve (Fig. 1). This curve shows a plateau region that is nearly flat, corresponding to a constant CBF for changes in MABP over a physiological range (50–170 mm Hg). The most frequently used methods for estimating changes in cerebral perfusion are TCD ultrasonography, xenon-133 clearance, and stable xenon CT–demonstrated CBF. Transcranial Doppler ultrasonography insonation of the MCA is probably the most convenient technique to use in the neurointensive care unit given that the MCA is most likely to be “visible” to the ultrasound through the thin part of the temporal bone. Other techniques reported
to reflect tissue perfusion include the AVDO₂ to estimate CBF changes, electromagnetic flow meters, near-infrared spectroscopy, laser Doppler flowmetry, and jugular venous occlusion plethysmography.

Using TCD ultrasonography to assess cerebral pressure autoregulation, the sROR is calculated as \( \% \text{ΔCVR}/\% \text{ΔCPP} \), where \%ΔCVR is the percentage of estimated change in CVR and can be calculated as \%ΔCPP = CBF \times \%ΔCVR and \%ΔCPP = MABP – ICP.\(^4\)

If the change in CPP were enough to compensate for the decrease in CPP, the sROR would be 1. Conversely, the absence of vasoconstriction in response to a drop in CPP would yield an sROR of 0. In other words, when cerebral autoregulation is intact, an equal change in CVR results in an sROR of 1. Conversely, in a pressure-passive circulation (absent autoregulation), no changes in CVR take place and sROR = 0. Under physiological conditions in humans (intact autoregulation), sROR ranges from 0.85 to 0.95.\(^5\) In TBI, the static criterion sROR > 0.5–0.85 represents a largely intact autoregulation.\(^3,4,2\)

*Dynamic Autoregulation*

One important variable that influences the autoregulatory response is time, and this dynamic autoregulation is probably more clinically important than static measures. The first means of assessing dynamic autoregulation was the thigh cuff deflation method, in which a decrease in MABP was the stimulus to study the temporal evolution of the CBF response.\(^1\) This method is used to describe transient changes in CBF after rapid changes in MABP. According to this procedure, there is a starting delay of 2 seconds, taking up to 10–15 seconds for the baroreflex mechanism to restore pressure to its previous level. In the normal brain, CBF volume returns to its baseline level much sooner than does MABP, and the speed of recovery is affected by PaCO₂ levels. With the dynamic method, it is also possible to characterize the interaction between pressure autoregulation and other variables such as PCO₂ and pharmacological agents (Fig. 4).

The index adopted to measure dynamic autoregulation is the equivalent of that for sROR and is defined as \((\Delta \text{CVR}/\Delta T)/\Delta \text{MABP} \), where \( T \) is time.

The thigh cuff inflation/deflation approach presents problems in the traumatically brain-injured patient, the most prominent of which is that it requires the manipulation of MABP at a time when the injured brain may least be able to tolerate it. Thus, investigators have sought alternative dynamic measures of autoregulation, often leveraging data already collected through multimodal neuromonitoring.

The Mx is one such measure of dynamic autoregulation. It is a Pearson correlation coefficient between CPP and flow velocity and can indicate autoregulation if the magnitude of slow CPP fluctuations is reasonably large enough to activate an autoregulatory response (> 5 mm Hg). Positive values of the Mx indicate that a change in blood flow velocity is accompanied by a parallel change in CPP—for example, when autoregulation is impaired. Zero or negative values indicate intact autoregulation. This index is valid and correlates significantly with the leg cuff test, PaCO₂ reactivity.\(^4\) The Mx is calculated from ICP, MABP, and TCD ultrasonography data obtained from the patient in real time.

The PRx is defined as the correlation coefficient between slow waves in ICP and arterial blood pressure. It describes cerebral vasoreactivity and the level of disturbance in physiological vascular responses to changes in MABP. The PRx correlates well with cerebral autoregulation assessed with PET-demonstrated CBF and TCD ultrasonography.\(^2,2\) In normal conditions, when the vascular bed is reactive, a decrease in MABP produces autoregulatory vasodilation and subsequent increases in CBV and ICP, the latter subject to the pressure-volume characteristic. Therefore, for a reactive vascular bed, the PRx is negative. For a nonreactive vascular bed, the PRx is positive, indicating passive transmission between slow waves of MABP and ICP. The mortality rate is higher in patients with severe TBI and a positive PRx (no reactivity) than in those in whom reactivity is preserved.\(^1\) Changes in the PRx over time indicate changes in pressure reactivity and may guide the treatment of patients. Steiner and colleagues\(^5\) are currently developing a commercial system for the online measurement of the PRx in patients. This group has published several reports validating the PRx and its relationship to the pathophysiology of neurological insults, including outcome, in the intensive care unit. A detailed description of the system for calculating the PRx based on multimodal neuromonitoring can be found at http://www.neurosurg.cam.ac.uk/icmplus.

*Diagnosis of Abnormal Cerebral Autoregulation and its Role in TBI Management*

Two modalities are currently used in clinical practice to assess cerebral autoregulation: continuous TCD ultrasonography monitoring and PRx monitoring. With continuous TCD ultrasonography monitoring, autoregulation can be monitored online, and any detrimental changes in its state can be interpreted as a warning sign. The ability to monitor serially and grade the autoregulatory response over time is unique to dynamic autoregulatory studies. Transcranial Doppler ultrasonography monitoring is convenient for testing autoregulation in critically ill patients because it requires minimal perturbation in MABP and because it can be easily performed in the intensive care unit.\(^2\) The dynamic ARI has been shown to correlate closely with the sROR, which has been considered an accurate reflection of cerebral autoregulation.

In clinical practice, it is not always clear what therapeutic actions best mitigate secondary injury. Certainly, an individual patient’s optimal CPP is an important parameter. The PRx provides a means of identifying the appropriate CPP treatment strategy for a given patient. Pressure reactivity can be quantified as the slope of the regression line relating MABP and ICP. As mentioned above, Steiner and colleagues\(^5\) are developing a commercial device for invasive PRx monitoring.

Patients with intact cerebral autoregulation, with a PRx slope < 0.13, respond best to hypertensive CPP-oriented therapy. Patients with impaired autoregulation, with a PRx slope > 0.13, may have a better outcome with
hypotensive ICP-oriented therapy, such as the Lund protocol.\textsuperscript{22} As mentioned above, this observation has been incorporated into the most recent guidelines for the management of severe TBI.\textsuperscript{7,8}

The normal 100 mm Hg–wide sROR range (50–150 mm Hg) can be reduced to a 10 mm Hg–wide autoregulation range in severe TBI. For each individual patient, this autoregulatory range can also change during the intensive care unit stay. Cerebral perfusion pressure and ICP management should therefore be individually tailored, and optimal CPP and cerebral autoregulation should be reassessed throughout the treatment course.

How to Restore Impaired Cerebral Autoregulation in a Patient With TBI

Hyperventilation

In a patient with TBI, hyperventilation improves autoregulation, but this improvement is not homogeneous or long lasting or well documented. The exact time and duration of the therapy required to achieve optimal improvement in cerebral autoregulation requires further characterization. Decreasing the PCO\textsubscript{2} values from a baseline of 37 to 28 mm Hg results in an improvement in the dynamic ARI.\textsuperscript{38}

The mechanism of improvement in autoregulation induced by hyperventilation is not clear. Possible mechanisms to account for this improvement may include an improved CPP, alterations in the pH value of the CSF, and increased vascular tone.\textsuperscript{37} If hyperventilation significantly reduced the ICP, then an increase in the CPP might contribute to an improvement in autoregulation. Another possible mechanism for improved autoregulation is the effect of hyperventilation on metabolic mediators.\textsuperscript{15} The shift in the acid-base balance in CSF induced by hyperventilation theoretically could affect the efficiency of the autoregulatory response. Increased arterial vascular tone might also improve the efficiency of the autoregulatory response by changing the set point of the regulating vessels to a more favorable position that would allow a rapid change in vascular resistance.

Autoregulation was found to be preserved at a moderately reduced PCO\textsubscript{2} (34 mm Hg) but was impaired when PCO\textsubscript{2} was reduced to low levels (23 mm Hg) by more intense hyperventilation.\textsuperscript{38} If an improvement in autoregulation is the result of enhanced vascular tone induced by hypocapnia, then this improvement can be lost if the vascular tone returns to baseline. Moreover, a recent prospective randomized trial of chronic hyperventilation for 5 days in severely head-injured patients did not show a benefit from this treatment. The use of hyperventilation to recover autoregulation reserve has been criticized because it can contribute to cerebral ischemia, as indicated by a lower CBF and higher O\textsubscript{2} extraction. Hyperventilation is probably only transiently effective.

Hyperoxia

A decrease in CBF after the induction of hyperoxia ranges from 13 to 32\%, and some authors have assumed that the decrease in blood flow during hyperoxia is induced by a decrease in ETCO\textsubscript{2}. Floyd et al.\textsuperscript{16} have shown that the decrease in CBF while breathing 100\% O\textsubscript{2} is attributable to the combination of arterial hyperoxia and hypocapnia and that hyperoxia causes a cerebral vasoconstriction independent of the vasoconstriction associated with arterial hypocapnia. The decrease in ICP and flow velocity is probably due to the vasoconstricting effects of hyperoxia, and a small decrease in ETCO\textsubscript{2} is caused by breathing 100\% O\textsubscript{2}. Hyperoxia is followed by an increase in jugular venous O\textsubscript{2} saturation and a decrease in AVDO\textsubscript{2}, suggesting that the ratio between O\textsubscript{2} demand and supply is shifted to either a lower cerebral metabolic rate of O\textsubscript{2} consumption or an improved delivery.\textsuperscript{5}

The increase in brain tissue O\textsubscript{2} tension after hyperoxia varies between patients and over time for each patient. The increase in brain tissue O\textsubscript{2} tension with hyperoxia appears to be much greater in pathological than in normal
brain tissue. Other studies have suggested that CBF at the site of the PO2 probe might explain these observations. There are significant changes in ARI in response to hyperoxia throughout the first few days after injury. Hyperoxia can restore cerebral autoregulation, but overall its effect is limited.

Nitric Oxide, L-Arginine, and Other NOS Drugs

Nitric oxide has multiple and complex roles in the pathophysiology of TBI. It is a cell membrane-permeable free radical synthesized from the amino acid L-arginine by the enzyme NOS. Nitric oxide plays a role in numerous general physiological processes of the brain, including the maintenance of basal vasomotor tone, selective neuroprotection, synaptogenesis, and synaptic plasticity. The role of NO in cerebral autoregulation is very controversial. Under pathological conditions, both excesses and deficiencies of NO may have deleterious effects. The depletion of NO produced by endothelial NOS could result in inadequate cerebral perfusion, whereas excesses in NO produced by neuronal NOS and iNOS could lead to neurotoxicity and cellular injury. Such changes in NO metabolism have been implicated in the pathophysiological changes occurring after TBI.

A triphasic (high-low-high) change in the concentration of NO in the brain has been observed after TBI. An immediate increase in NO concentration has occurred within minutes after TBI in experimental models. This phase has been followed by an early decrease (0.5–6 hours) in NO concentrations, which may in part account for the low CBF observed during this period after injury. The decrease in NO can result from either a decrease in NO production or rapid inactivation of NO. The late phase (> 6 hours) is an increase in NO associated with a return to normal or even elevated levels of CBF. Elevated expression of iNOS protein in cerebrovascular smooth muscles has been observed during this phase, and CSF levels of NO have been reported to peak between 20 and 42 hours after TBI.

During the early phase, a period of relative deficiency in NO and a low level of CBF, the administration of L-arginine has been shown to improve CBF and neurological outcome in models of TBI. During the late peak in NO after TBI due to the activity of iNOS, the inhibition of iNOS has been neuroprotective in experimental models of TBI.

Erythropoietin

Erythropoietin has been shown to be a neuroprotector and reduce neuronal death in many in vivo and in vitro models. The overall expression of erythropoietin receptors by neurons, astrocytes, and capillary endothelial cells elicited by hypoxia and ischemia supports a hypothetically well-organized network in the setting of neuronal injury. Experimental studies have shown that erythropoietin can induce a significant reduction in inflammation and neuronal apoptosis; decrease necrosis, brain edema, and capillary breakdown; and restore cerebral autoregulation. The use of erythropoietin in TBI may hold promise for future clinical applications.

L. Rangel-Castilla et al.

Conclusions

In the absence of a gold-standard method of assessing cerebral autoregulation, additional studies are necessary to establish the accuracy of different measures of cerebral autoregulation in patients with TBI.

Cerebral autoregulation is seen as a protective mechanism; however, its exact role in secondary injury after TBI is not known. Cerebral autoregulation is altered after injury, but more information is needed regarding its role as a causative agent and a factor in guiding therapy as well as the determinants of outcome in TBI. Nevertheless, cerebral autoregulation is one of the multiple factors involved in the pathophysiology of TBI. Further investigations are required to analyze and measure a multivariate dynamic method of describing interrelationships with other factors involved in cerebral vasculature.

A desirable pharmacological therapy would induce a lasting reduction in CBV with a minimal effect on CBF. This drug would have its principle vasoconstriction within the venous compartment, where 70% of the blood volume is located.

The inclusion of cerebral autoregulation in multimodal neuromonitoring of the traumatically brain-injured patient is approaching "prime time," and an appreciation of the interplay between the cerebral autoregulation status and critical care management may aid in the individualization of treatment for severe TBI.

Disclaimer

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Acknowledgment

The authors are grateful to Brodus Franklin, B.S., for assistance in the preparation of Figs. 1 and 2.

References


Neurosurg. Focus / Volume 25 / October 2008
Cerebral autoregulation in traumatic brain injury


*Address correspondence to:* Leonardo Rangel-Castilla, M.D., Division of Neurosurgery, University of Texas Medical Branch, 301 University Boulevard, John Sealy Annex, Suite 9.121 ZC, Galveston, Texas 77555. email: lerangel@utmb.edu.